For Researchers
Accelerating practice-changing discoveries in cancer care
Grant Opportunities
Learn more about the spectrum of funding programs from Gateway
Apply For a GrantGrant Management
Access grant applications, review submissions and clinical trial progress
Log In NowA Patient-Centric Funding Approach
Gateway for Cancer Research is one of the only nonprofits that exclusively funds Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type or stage. The organization invests in next generation science – research that is often underfunded, with strong potential to change standards of care.
Patient-Centered Research
At Gateway, everything we do is always and only about the patient. Patient representatives sit at every level of the organization, and clinician-scientists are incentivized to place patients at the center of their work.
Transformational Science
Early-phase clinical trials are at the forefront of the research and discovery process. Gateway-funded trials bring potentially life-saving breakthroughs to the bedside of patients at renowned institutions around the world.
Holistic Treatment
Gateway funds integrative therapies that promote treatment while supporting quality of life. This evidence-based research combines conventional and complementary treatments to mitigate side effects and help improve treatment tolerance while combating the underlying disease.
Our Focus on Patients
At Gateway, we are committed to empowering patients to triumph over their disease. To ensure patient voices are being amplified in funded research, we require each trial to place patients at the center of their work.
All Gateway-funded trials should:
What Gateway is doing has extreme value and is very significant for us as investigators, as well as all the patients and their families who are in critical need of better therapies.
Latest Research
Gateway only invests in Phase I and Phase II human clinical trials where true innovation and transformational discoveries happen.
Trial Type: Lung Cancer
Identification of Predictive Biomarkers to Prevent Pneumonitis in Patients with Non-Small Cell Lung Cancer Who are Receiving Immunotherapy (Phase II)
Ajay Sheshadri, MD
The University of Texas MD Anderson Cancer Center
Trial Type: Pancreatic Cancer
Novel Use of Pepinemab in Combination with Nivolumab and FOLFIRINOX Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma (Phase Ib/II)
David Linehan, MD
University of Rochester
Research FAQs
Browse frequently asked questions about research programs offered by Gateway
Read More